Effect of adjuvant transarterial chemoembolization on survival in hepatocellular carcinoma with microvascular invasion: a landmark analysis
Related Experiment Video
Updated: Jun 9, 2026
Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
Published on: September 20, 2020
Tian-Chen Zhang1,2, Wei-Li Jia1,2, Yu Cao2
1The First School of Clinical Medicine, First Affiliated Hospital of Lanzhou University, Lanzhou, China.
Background:
The prognostic significance of adjuvant transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC) patients with microvascular invasion (MVI) remains controversial. Furthermore, current literature often overlooks the treatment timing, and conventional survival analyses fail to address the immortal time bias introduced by delayed TACE initiation. This study aimed to evaluate the true clinical value of adjuvant TACE after adjusting for this bias.
Methods:
This retrospective multicenter study included 512 HCC patients with MVI who underwent curative hepatectomy with or without adjuvant TACE between 2018 and 2024. Propensity score matching (PSM) was used to balance baseline characteristics. To rigorously adjust for immortal time bias, landmark analysis at 2-, 4-, 6-, and 12-month after surgery, along with time-dependent Cox regression (TDC) analysis, was performed.
Results:
In the entire cohort, conventional Kaplan-Meier analysis showed better overall survival (OS) and recurrence-free survival (RFS) in the TACE group than in the NO-TACE group (all p < 0.05). However, landmark analysis showed improved OS at the 4-, 6-, and 12-month landmarks (HR 0.68, 0.70, 0.69, respectively), whereas RFS differed significantly only at the 6-month landmark (p = 0.020). TDC analysis showed that adjuvant TACE was associated with improved OS (HR 0.63, 95% CI 0.47-0.85, p = 0.002) but not RFS. In the subgroup with tumor size ≥ 5 cm, landmark analysis showed significant advantages in both OS and RFS (all p < 0.05), and TDC analysis further revealed that adjuvant TACE was linked to improved OS (HR 0.46, 95% CI 0.30-0.69, p < 0.001) and RFS (HR 0.66, 95% CI 0.47-0.92, p = 0.014).
Conclusion:
Adjuvant TACE was associated with improved OS in HCC patients with MVI, particularly in high-risk patients with tumor size ≥ 5 cm, who showed consistent improvements in both OS and RFS. The potential benefit of adjuvant TACE may extend beyond the conventional early postoperative period in MVI patients with tumor size ≥ 5 cm.
